PIRENOXINE SODIUM

Details

Stereochemistry	ACHIRAL
Molecular Formula	C16H7N2O5.Na
Molecular Weight	330.2269
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[Na+].OC1=CC(=NC2=C1C3=NC4=CC=CC=C4OC3=CC2=O)C([O-])=O

InChI

InChIKey=HDQXPMXHXZNPKE-UHFFFAOYSA-M

InChI=1S/C16H8N2O5.Na/c19-9-5-8(16(21)22)18-14-10(20)6-12-15(13(9)14)17-7-3-1-2-4-11(7)23-12;/h1-6H,(H,18,19)(H,21,22);/q;+1/p-1

HIDE SMILES / InChI

Molecular Formula	Na
Molecular Weight	22.9898
Charge	1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H7N2O5
Molecular Weight	307.2372
Charge	-1
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160
Curator's Comment: description was created based on several sources, including, http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9

Pirenoxine is an anti-cataract agent which is used in many asian countries under the name Catalin. Although its efficacy is not proved scientifically, the drug may play an important role in cataract prevention. It is supposed that the anti-cataract effect of pirenoxine results from inhibition of sulfhydryl combination of quinoid substances with lens proteins and the inhibition leads to the maintenance of lens transparency.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
maintenance of lens transparency 2 Target ID: GO:0036438 Sources: http://www.ncbi.nlm.nih.gov/pubmed/21850160	Activator 1430

Conditions

Condition	Modality	Targets	Highest Phase	Product
Senile cataract 2 Sources: http://www.fda.gov.tw/MLMS/ShowFile.aspx?LicId=02021053&Seq=007&Type=9	Preventing		Approved 8429	CATALIN Approved Use Early stage of senile cataract.

PubMed

Title	Date	PubMed
[Efficacy of catalin eyed drops in age-related cataract agents].	2010 Jan-Feb	20645574

Patents

Sample Use Guides

In Vivo Use Guide

Dissolve the granules (0.75 mg) in 15 ml of the vehicle just before use and instill 1-2 drops of the solution, 3-5 times a day

Route of Administration: Other

In Vitro Use Guide

Pirenoxine (1,000 uM) decreased UVC-induced turbidity formation compared to controls after 4 h of UVC exposure. The absolute gamma-crystallin turbidity induced by 4 h of UVC exposure was ameliorated in the presence of catalin equivalent to 1-100 uM of the drug in a concentration-dependent manner. Pirenoxine at 0.03, 0.1, and 0.3 uM significantly delayed 10 mM selenite- and calcium-induced turbidity formation compared to controls on days 0-4.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 18:46:02 GMT 2023` Edited by `admin` on `Fri Dec 15 18:46:02 GMT 2023`
Record UNII	95JU7URF64
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PIRENOXINE SODIUM

Common Name

English

5H-PYRIDO(3,2-A)PHENOXAZINE-3-CARBOXYLIC ACID, 1-HYDROXY-5-OXO-, MONOSODIUM SALT

Common Name

English

PIRENOXINE SODIUM SALT

Common Name

English

CATALIN SODIUM

Common Name

English

SODIUM 1-HYDROXY-5-OXO-5H-PYRIDO(3,2-A)(PHENOXAZINE-3-CARBOXYLATE

Common Name

English

PIRENOXINE SODIUM SALT [MI]

Common Name

English

5H-PYRIDO(3,2-A)PHENOXAZINE-3-CARBOXYLIC ACID, 1-HYDROXY-5-OXO-, SODIUM SALT (1:1)

Common Name

English

PIRFENOXONE SODIUM

Common Name

English

Pirenoxine sodium [WHO-DD]

Common Name

English

PIRFENOXONE SODIUM SALT

Common Name

English

PIRENOXINE SODIUM [MART.]

Common Name

English

Code System Code Type Description

PUBCHEM

23695982